IDEAS home Printed from https://ideas.repec.org/a/wly/hlthec/v14y2005i3p217-230.html
   My bibliography  Save this article

Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data

Author

Listed:
  • Adrian Bagust
  • Sophie Beale

Abstract

Recent research has employed different analytical techniques to estimate the impact of the various long‐term complications of type 2 diabetes on health‐related utility and health status. However, limited patient numbers or lack of variety of patient experience has limited their power to discriminate between separate complications and grades of severity. In this study alternative statistical model forms were compared to investigate the influence of various factors on self‐assessed health status and calculated utility scores, including the presence and severity of complications, and type of diabetes therapy. Responses to the EuroQol EQ‐5D questionnaire from 4641 patients with type 2 diabetes in 5 European countries were analysed. Simple multiple regression analysis was used to model both visual analogue scale (VAS) scores and time trade‐off index scores (TTO). Also, two complex models were developed for TTO analysis using a structure suggested by the EuroQol calculation algorithm. Both VAS and TTO models achieved greater explanatory power than in earlier studies. Relative weightings for individual complications differed between VAS and TTO scales, reflecting the strong influence of loss of mobility and severe pain in the EuroQol algorithm. Insulin‐based therapy was uniformly associated with a detrimental effect equivalent to an additional moderate complication. Evidence was found that TTO values are not responsive in cases where 3 or more multiple complications are present, and therefore may underestimate utility loss for patients most adversely affected by complex chronic diseases like diabetes. Copyright © 2004 John Wiley & Sons, Ltd.

Suggested Citation

  • Adrian Bagust & Sophie Beale, 2005. "Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 217-230, March.
    • Handle: RePEc:wly:hlthec:v:14:y:2005:i:3:p:217-230
    DOI: 10.1002/hec.910
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/hec.910
    Download Restriction: no
    File URL: https://libkey.io/10.1002/hec.910?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Paul Dolan & Claire Gudex & Paul Kind & Alan Williams, 1995. "A social tariff for EuroQol: results from a UK general population survey," Working Papers 138chedp, Centre for Health Economics, University of York.
    2. Philip Clarke & Alastair Gray & Rury Holman, 2002. "Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)," Medical Decision Making, , vol. 22(4), pages 340-349, August.
    3. Xavier Badia & Montserrat Roset & Michael Herdman & Paul Kind, 2001. "A Comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States," Medical Decision Making, , vol. 21(1), pages 7-16, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Richard F. Pollock & William J. Valentine & Steven P. Marso & Andreas Andersen & Jens Gundgaard & Nino Hallén & Deniz Tutkunkardas & Elizabeth A. Magnuson & John B. Buse, 2019. "Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)," Applied Health Economics and Health Policy, Springer, vol. 17(5), pages 615-627, October.
    2. Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen, 2020. "Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out," PharmacoEconomics, Springer, vol. 38(9), pages 953-969, September.
    3. Tessa Peasgood & Alan Brennan & Peter Mansell & Jackie Elliott & Hasan Basarir & Jen Kruger, 2016. "The Impact of Diabetes-Related Complications on Preference-Based Measures of Health-Related Quality of Life in Adults with Type I Diabetes," Medical Decision Making, , vol. 36(8), pages 1020-1033, November.
    4. Ulf Persson & Michael Willis & Knut Ödegaard, 2010. "A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 195-203, April.
    5. Åsa Ericsson & Divina Glah & Maria Lorenzi & Jeroen P Jansen & Adam Fridhammar, 2018. "Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes," PLOS ONE, Public Library of Science, vol. 13(2), pages 1-16, February.
    6. Scott Doyle & Andrew Lloyd & Lee Moore & Joshua Ray & Alastair Gray, 2012. "A Systematic Review and Critical Assessment of Health State Utilities," PharmacoEconomics, Springer, vol. 30(12), pages 1133-1143, December.
    7. Sara Stafford & Peter G. Bech & Adam Fridhammar & Nino Miresashvili & Andreas Nilsson & Michael Willis & Aiden Liu, 2022. "Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting," Applied Health Economics and Health Policy, Springer, vol. 20(4), pages 543-555, July.
    8. Phil McEwan & Hayley Bennett & Jonathan Fellows & Jennifer Priaulx & Klas Bergenheim, 2016. "The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-14, September.
    9. Gemma Shields & Stephen Beard, 2015. "A Systematic Review of the Economic and Humanistic Burden of Gout," PharmacoEconomics, Springer, vol. 33(10), pages 1029-1047, October.
    10. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    11. Phil McEwan & Jason Gordon & Marc Evans & Thomas Ward & Hayley Bennett & Klas Bergenheim, 2015. "Estimating Cost-Effectiveness in Type 2 Diabetes," Medical Decision Making, , vol. 35(5), pages 660-670, July.
    12. Melanie J. Davies & Divina Glah & Barrie Chubb & Gerasimos Konidaris & Phil McEwan, 2016. "Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting," PharmacoEconomics, Springer, vol. 34(9), pages 953-966, September.
    13. Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter, 2019. "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada," PharmacoEconomics - Open, Springer, vol. 3(4), pages 537-550, December.
    14. Åsa Ericsson & Adam Lundqvist, 2017. "Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 237-248, April.
    15. Chen-Wei Pan & Hong-Peng Sun & Hui-Jun Zhou & Qinghua Ma & Yong Xu & Nan Luo & Pei Wang, 2016. "Valuing Health-Related Quality of Life in Type 2 Diabetes Patients in China," Medical Decision Making, , vol. 36(2), pages 234-241, February.
    16. Hui Shao & Shuang Yang & Vivian Fonseca & Charles Stoecker & Lizheng Shi, 2019. "Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation," PharmacoEconomics, Springer, vol. 37(7), pages 921-929, July.
    17. Alison J. Hayes & Philip M. Clarke & Merryn Voysey & Anthony Keech, 2011. "Simulation of Quality-Adjusted Survival in Chronic Diseases," Medical Decision Making, , vol. 31(4), pages 559-570, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
    2. John Yfantopoulos & Athanasios Chantzaras, 2020. "Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 729-743, July.
    3. Marian Sorin Paveliu & Elena Olariu & Raluca Caplescu & Yemi Oluboyede & Ileana-Gabriela Niculescu-Aron & Simona Ernu & Luke Vale, 2021. "Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off," IJERPH, MDPI, vol. 18(14), pages 1-16, July.
    4. José M. Labeaga & Xisco Oliver & Amedeo Spadaro, "undated". "Measuring Changes in Health Capital," Working Papers 2005-15, FEDEA.
    5. Richard Norman & Paula Cronin & Rosalie Viney & Madeleine King & Deborah Street & John Brazier & Julie Ratcliffe, 2007. "Valuing EQ-5D health states: A review and analysis, CHERE Working Paper 2007/9," Working Papers 2007/9, CHERE, University of Technology, Sydney.
    6. Mason, J.E. & Denton, B.T. & Shah, N.D. & Smith, S.A., 2014. "Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients," European Journal of Operational Research, Elsevier, vol. 233(3), pages 727-738.
    7. Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés, 2013. "Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 33-42, July.
    8. Gisela Kobelt & J. Berg & P. Lindgren, 2006. "Costs and quality of life in multiple sclerosis in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 55-64, July.
    9. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    10. Lieven Annemans & Mélanie Brignone & Sylvain Druais & Ann Pauw & Aline Gauthier & Koen Demyttenaere, 2014. "Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium," PharmacoEconomics, Springer, vol. 32(5), pages 479-493, May.
    11. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
    12. Mathieu F. Janssen & Ines Buchholz & Dominik Golicki & Gouke J. Bonsel, 2022. "Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries," PharmacoEconomics, Springer, vol. 40(11), pages 1081-1093, November.
    13. José Nunes, 1998. "Economic evaluation of rehabilitation: The quality of life approach using EuroQol," International Advances in Economic Research, Springer;International Atlantic Economic Society, vol. 4(2), pages 192-201, May.
    14. Brian T. Denton & Murat Kurt & Nilay D. Shah & Sandra C. Bryant & Steven A. Smith, 2009. "Optimizing the Start Time of Statin Therapy for Patients with Diabetes," Medical Decision Making, , vol. 29(3), pages 351-367, May.
    15. Mathieu F. Janssen & A. Simon Pickard & James W. Shaw, 2021. "General population normative data for the EQ-5D-3L in the five largest European economies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1467-1475, December.
    16. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    17. Lena Lundberg & Magnus Johannesson & Dag G.L. Isacson & Lars Borgquist, 1999. "The Relationship between Health-state Utilities and the SF-12 in a General Population," Medical Decision Making, , vol. 19(2), pages 128-140, April.
    18. Irina Cleemput, 2010. "A social preference valuations set for EQ-5D health states in Flanders, Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 205-213, April.
    19. Shuyan Gu & Yiming Mu & Suodi Zhai & Yuhang Zeng & Xuemei Zhen & Hengjin Dong, 2016. "Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-25, November.
    20. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:14:y:2005:i:3:p:217-230. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.